Shengnan Lv

TUDCA was identified as a potential therapeutic drug for nonalcoholic steatohepatitis complicated with hypercholesterolemia targeting ADRA2C by integrated bioinformatics and experimental verification

Abstract Nonalcoholic steatohepatitis (NASH) is a type of liver disease in which fat accumulates in the liver with inflammation. Hypercholesterolemia is a common autosomal dominant inherited metabolic disease. Previous studies have suggested a potential association between NASH a...